Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update
Announced Publication of ADXS-PSA Data in The Oncologist Presented Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in...